Physician profile
James Leek
NPI 1528042033
$2,135.94
in general payments reported to CMS, 2019-2025
15 companies · $84.05 in 2025
The $84.05 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2021: $229 · 2022: $163 · 2023: $178 · 2024: $227 · 2025: $84.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,053.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.58 | 2021-2023 | Relistor |
| Averitas Pharma INC. | $111.96 | 2023-2024 | Qutenza |
| Collegium Pharmaceutical, INC. | $108.82 | 2022 | |
| Abbvie INC. | $104.87 | 2021-2023 | |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Pfizer INC. | $81.55 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $79.55 | 2024 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Allergan, INC. | $65.31 | 2019 | |
| Smith+Nephew, INC. | $62.50 | 2019 | |
| Scilex Pharmaceuticals INC. | $58.79 | 2019 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Baudax Bio INC. | $18.69 | 2021 | |
| Medtronic USA, INC. | $15.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Leek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.